Efflux-Resistant Antibiotics May Revive Treatment

Medically reviewed | Published: | Evidence level: 1A
Researchers at King's College London have described a preclinical antibiotic-design platform that modifies drugs so bacteria are less able to pump them out of the cell. The approach could help revive older antibiotic classes, but it remains an early-stage treatment advance rather than an approved therapy.
📅 Published:
Reviewed by iMedic Medical Editorial Team
📄 Infectious Disease

Quick Facts

AMR Deaths
1.27 million/year
Evidence Stage
Preclinical proof-of-concept
Design Target
Efflux pumps

How could efflux-resistant antibiotics treat resistant infections?

Quick answer: They are designed to stay inside bacterial cells despite resistance pumps that normally push antibiotics out.

Many drug-resistant bacteria survive treatment by lowering the intracellular concentration of an antibiotic before it can fully act. Efflux pumps are membrane proteins that export drugs from the bacterial cell, and they can contribute to reduced susceptibility across several antibiotic classes, including fluoroquinolones and tetracyclines.

The King's College London work focuses on building resistance-breaking properties into the antibiotic molecule itself. That differs from older strategies that attempted to pair antibiotics with separate efflux pump inhibitors, an approach that has often been limited by toxicity, selectivity, and pharmacology problems.

Why is this antibiotic research clinically important?

Quick answer: It addresses a resistance mechanism that can make existing antibiotics fail even when the original drug target remains vulnerable.

Antimicrobial resistance is already a major cause of death worldwide. The 2019 Global Burden of Disease analysis estimated that bacterial antimicrobial resistance was directly responsible for about 1.27 million deaths and associated with about 4.95 million deaths globally.

If efflux-resistant chemistry can be translated into safe medicines, it could expand the usefulness of established antibiotic scaffolds instead of relying only on entirely new classes. That matters because antibiotic development is slow, commercially difficult, and especially urgent for infections caused by multidrug-resistant Gram-negative bacteria.

What should patients know before expecting new antibiotics?

Quick answer: The approach is promising, but it still needs human safety, dosing, and efficacy trials before it can change routine care.

The reported work should be viewed as drug-discovery progress, not a treatment available in clinics. Preclinical activity against resistant bacteria can fail later if a compound has poor absorption, toxicity, drug interactions, or inadequate tissue penetration in humans.

For patients, the practical message remains unchanged: antibiotics should be used only when clinically indicated, taken exactly as prescribed, and avoided for viral illnesses. Stewardship is still essential because even well-designed new antibiotics can lose effectiveness if they are overused.

Frequently Asked Questions

No. The current work is preclinical and would need formal clinical trials before any drug could be approved for patients.

No. It is a design strategy that may improve selected antibiotic classes, but treatment will still depend on the infection site, bacterial species, resistance testing, and patient safety factors.

References

  1. King's College London. Novel Antibiotic Design Targets Drug-Resistant Infections. May 29, 2026. https://www.miragenews.com/novel-antibiotic-design-targets-drug-resistant-1682983/
  2. Laws M, Hind C, Nahar K, Clifford M, Marsh C, Xu M, et al. Efflux Resistance Breakers: A New Technology to Overcome Efflux-Mediated Resistance in Multidrug Resistant Bacteria. ChemRxiv. 2025. https://doi.org/10.26434/chemrxiv-2025-gsw00
  3. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022;399:629-655. https://doi.org/10.1016/S0140-6736(21)02724-0